Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepaGrowth
2024-516572-15-00Phase 4Authorised
- Sponsor
- ULS São José
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of enoxaparin sodium in intrauterine growth restriction (IUGR) (2 arms), sponsored by ULS São José. Primary endpoint: Gestational age at delivery. Planned start Sep 2024; status: authorised.
02
Drugs
enoxaparin sodium
03
Conditions
intrauterine growth restriction (IUGR)
Beyond the preview
Go deeper on 2024-516572-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516572-15-00.